- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about MRK
Recent news which mentions MRK
Merck's Gardasil Shot Challenges To Continue, Analysts Optimistic For Newly Approved Sotatercept For Rare Lung Disease
November 01, 2024
From Benzinga
Stocks Tumble, Nasdaq 100 Selloffs As Tech Giants Disappoint, Crypto Companies Plummet: What's Driving Markets Thursday?
October 31, 2024
From Benzinga
Merck Beats Q3 Estimates, But Lowers Annual Forecast As Gardasil Vaccine Hit By Low China Demand
October 31, 2024
From Benzinga
3 Dividend Stocks That Could Raise Their Payouts in November
October 31, 2024
From Motley Fool
A Look Into Merck & Co Inc's Price Over Earnings
October 29, 2024
From Benzinga
Why Is Moderna Stock Trading Higher On Monday?
October 28, 2024
From Benzinga
Pfizer, Live Nation Entertainment And More On CNBC's 'Final Trades'
October 25, 2024
From Benzinga
CDC And Prevention Advisory Panel Backs Expanded Use Of Pfizer And Merck's Pneumococcal Vaccines
October 24, 2024
From Benzinga
3 Absurdly Cheap Stocks That Pay High Dividends
October 24, 2024
From Motley Fool
800% Upside For This Biotech Stock - Analyst Initiates Coverage On Bladder Cancer Focused ImmunityBio
October 23, 2024
From Benzinga
Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks
October 21, 2024
From Benzinga
After Failed Confirmatory Trial, Gilead Withdraws US Accelerated Approval Of Trodelvy As Bladder Cancer treatment
October 18, 2024
From Benzinga
Merck Virus Treatment Shows 60.4% Effectiveness, Reduces Certain Infections In Infants
October 18, 2024
From Benzinga
Up 700% This Year, Is It Too Late to Invest in This Stock?
October 15, 2024
From Motley Fool
2 Incredibly Cheap Big Pharma Stocks to Buy Now
October 12, 2024
From Motley Fool
18 Stocks To Buy, 7 To Sell This Earnings Season: Goldman Sachs Calls It 'The Year Of The Stock Picker'
October 10, 2024
From Benzinga
Personalized Treatment And Immunotherapy Are Pharma's Newest Weapons Against Cancer
October 10, 2024
From Benzinga
Jim Cramer Says He's Buying 'Some Target,' But Dismisses SoundHound AI As 'Meme Stock'
October 09, 2024
From Benzinga
Merck's Mumps Vaccine Controversy: Class-Action Lawsuit Alleges Anticompetitive Behavior, Court Shields From Liability
October 08, 2024
From Benzinga
Merck Touts Phase 3 Success For $20B Cancer Drug Keytruda In Untreated Head And Neck Cancer Patients
October 08, 2024
Tickers
MRK
From Benzinga
10 Health Care Stocks Whale Activity In Today's Session
October 07, 2024
From Benzinga
2 Soaring Stocks That Could Climb Another 112% and 120%, According to Wall Street Analysts
October 07, 2024
From Motley Fool
Is It Time to Buy September's Worst-Performing Dow Jones Stocks?
October 05, 2024
From Motley Fool
Novo Nordisk/AstraZeneca's Manufacturing Partner Thermo Fisher Questioned Over Manufacturing Lapses
October 04, 2024
From Benzinga
Could Summit Therapeutics Become the Next Merck?
October 04, 2024
From Motley Fool
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.